Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to demonstrate the clinical efficacy of rozanolixizumab in maintenance treatment and assess safety and tolerability of rozanolixizumab in adult study participants with primary immune thrombocytopenia (ITP).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04224688
Study type Interventional
Source UCB Pharma
Contact
Status Terminated
Phase Phase 3
Start date June 3, 2020
Completion date May 5, 2022

See also
  Status Clinical Trial Phase
Completed NCT05621330 - Efficacy and Safety of QL0911 in Adult Patients With Chronic Primary Immune Thrombocytopenia Phase 3
Active, not recruiting NCT04278924 - A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia Phase 2
Recruiting NCT06148389 - The Safety and Tolerability of STSA-1301 Subcutaneous Injection in Healthy Subjects Phase 1
Active, not recruiting NCT04812925 - A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia Phase 3
Recruiting NCT06107582 - Longitudinal Cohort of Pediatric Primary Immune Thrombocytopenia (ITP)
Recruiting NCT05371743 - Plasma microRNA Levels and Some Cytokines Expression in Patients With ITP Primary Immune Thrombocytopenic Purpura (ITP)
Not yet recruiting NCT05333861 - An Observational, Multicenter Study to Evaluate the Safety and Effectiveness of Hetrombopag in Patients With ITP or AA
Not yet recruiting NCT05311930 - Efficacy and Safety of TPO Receptor Agonists in the Treatment of Elderly ITP Patients Phase 4
Not yet recruiting NCT06291415 - The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP) Phase 1
Completed NCT03102593 - A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP Phase 2
Completed NCT06071520 - Andalusian Experience in the Use of Fostamatinib in Patients With ITP. FOSTASUR Study
Recruiting NCT04949009 - Avatrombopag in the Treatment of Primary Immune Thrombocytopenia(ITP)
Active, not recruiting NCT04225156 - A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). Phase 3
Completed NCT05551624 - Evaluation of the Effect in Platelet Count of Atorvastatin and N-acetyl Cysteine Early Phase 1
Recruiting NCT05422365 - Intravenous Immunoglobulin (IVIG, Bioven) Efficacy and Safety in Chronic Primary Immune Thrombocytopenia (ITP) in Adults Phase 3
Terminated NCT03275740 - A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347 Phase 1
Terminated NCT04596995 - A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) Phase 3
Terminated NCT04200456 - A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) Phase 3
Recruiting NCT05653219 - A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids Phase 3
Completed NCT01727232 - Efficacy and Safety of Rituximab Given at Fixed Dose (1000 mg on Days 1 and 15) Compared to the Standard Regimen in Adult's Immune Thrombocytopenia N/A